Pyc Therapeutics Stock Revenue
| PYC Stock | 1.40 0.05 3.45% |
PYC Therapeutics fundamentals help investors to digest information that contributes to PYC Therapeutics' financial success or failures. It also enables traders to predict the movement of PYC Stock. The fundamental analysis module provides a way to measure PYC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PYC Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 22.1 M | 23.2 M |
PYC | Revenue |
PYC Therapeutics Company Revenue Analysis
PYC Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current PYC Therapeutics Revenue | 22.06 M |
Most of PYC Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PYC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of PYC
Projected quarterly revenue analysis of PYC Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of PYC Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in PYC Therapeutics' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
PYC Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, PYC Therapeutics reported 22.06 M of revenue. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The revenue for all Australia stocks is notably lower than that of the firm.
PYC Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PYC Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PYC Therapeutics could also be used in its relative valuation, which is a method of valuing PYC Therapeutics by comparing valuation metrics of similar companies.PYC Therapeutics is currently under evaluation in revenue category among its peers.
PYC Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.38 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.78) % | ||||
| Current Valuation | 587.49 M | ||||
| Shares Outstanding | 466.61 M | ||||
| Shares Owned By Insiders | 59.23 % | ||||
| Shares Owned By Institutions | 0.57 % | ||||
| Price To Book | 8.12 X | ||||
| Price To Sales | 29.61 X | ||||
| Revenue | 22.06 M | ||||
| Gross Profit | 15.81 M | ||||
| EBITDA | (38.12 M) | ||||
| Net Income | (37.73 M) | ||||
| Cash And Equivalents | 15.57 M | ||||
| Total Debt | 1.11 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (38.59 M) | ||||
| Earnings Per Share | (0.10) X | ||||
| Target Price | 8.75 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 653.25 M | ||||
| Total Asset | 91.24 M | ||||
| Retained Earnings | (155.89 M) | ||||
| Working Capital | 76.51 M | ||||
| Net Asset | 91.24 M |
About PYC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PYC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PYC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PYC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.